Naomi Kresge

Naomi Kresge is a reporter at Bloomberg News who covers the pharmaceutical industry and health-related topics. She has written extensively about Novo Nordisk, Eli Lilly, and other drug manufacturers, focusing on their new drugs and treatments as well as potential risks and controversies. Her articles often provide detailed explanations of medical studies and their implications for patients and healthcare providers.

Biography:  https://www.bloomberg.com/authors/APcZTBzhnK8/naomi-kresge

72%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

86%

Examples:

  • The author has a history of reporting on pharmaceutical companies and their products with a focus on the benefits and potential risks.
  • There is no evidence of any personal or financial ties between the author and the companies they report on.

Conflicts of Interest

50%

Examples:

  • There is no evidence of any personal or financial ties between the author and the companies they report on.

Contradictions

86%

Examples:

  • In one article, it was reported that patients who took Wegovy had fewer serious medical problems, while in another article it was stated that patients who took Ozempic had a lower risk of cancer.
  • The author has not addressed these contradictions in their reporting.

Deceptions

75%

Examples:

  • The author has also not provided full context for some of their reports, which may lead to confusion or misunderstanding.
  • The author has used misleading language in their reporting, such as stating that Wegovy 'eased heart failure symptoms' when in fact the study showed only a statistical significance for one of the secondary endpoints.

Recent Articles

New Study Finds Diabetes Drug Ozempic May Prevent Cognitive Decline and Substance Misuse

New Study Finds Diabetes Drug Ozempic May Prevent Cognitive Decline and Substance Misuse

Broke On: Friday, 12 July 2024 New studies suggest Novo Nordisk's diabetes drug Ozempic (semaglutide) may prevent cognitive decline and reduce substance misuse risks. Researchers found a 48% lower dementia risk for patients on Ozempic compared to sitagliptin or glipizide, and a lower risk of cognitive deficits and nicotine dependence. Novo Nordisk plans further studies on Alzheimer's disease.
Wegovy Effective in Treating Heart Failure Symptoms for Patients with Diabetes, Study Shows

Wegovy Effective in Treating Heart Failure Symptoms for Patients with Diabetes, Study Shows

Broke On: Saturday, 06 April 2024 Novo Nordisk's Wegovy has been found to be effective in treating heart failure symptoms for patients with diabetes. In a large trial, patients who took Wegovy reported less fatigue, leg swelling and shortness of breath than those who received a placebo. They were also able to walk farther in six minutes. Additionally, the study showed that Wegovy reduced serious medical problems among these patients.